PE20130324A1 - Proteinas de fusion que comprenden un antigeno prame (dage) - Google Patents

Proteinas de fusion que comprenden un antigeno prame (dage)

Info

Publication number
PE20130324A1
PE20130324A1 PE2012001372A PE2012001372A PE20130324A1 PE 20130324 A1 PE20130324 A1 PE 20130324A1 PE 2012001372 A PE2012001372 A PE 2012001372A PE 2012001372 A PE2012001372 A PE 2012001372A PE 20130324 A1 PE20130324 A1 PE 20130324A1
Authority
PE
Peru
Prior art keywords
fusion protein
amino acids
protein
dage
fusion proteins
Prior art date
Application number
PE2012001372A
Other languages
English (en)
Inventor
Normand Blaise
Denis Martin
Remi M Palmantier
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39300029&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20130324(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0700760A external-priority patent/GB0700760D0/en
Priority claimed from GB0701262A external-priority patent/GB0701262D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of PE20130324A1 publication Critical patent/PE20130324A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001189—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA PROTEINA DE FUSION QUE COMPRENDE: (a) UN PRAME O UN FRAGMENTO INMUNOLOGICO DEL MISMO QUE CONSTA DE UNO O MAS DE LOS EPITOPES SIGUIENTES: (i) VLDGLDVLL; (ii) SLYSFPEPEA ; ENTRE OTROS; (b) UNA PROTEINA PAREJA DE FUSION HETEROLOGA DERIVADA DE PROTEINA D QUE ESTA CONSTITUIDA POR LOS AMINOACIDOS 20 A 127 DE LA PROTEINA D Y LOS AMINOACIDOS LYS-21 Y LEU-22 ESTAN SUSTITUIDOS CON LOS AMINOACIDOS ASP-21 Y PRO-22; (C) UNA O MAS SECUENCIAS DE ENGARCE ENTRE LA PROTEINA FUSION Y EL ANTIGENO TUMORAL. REFERIDA ADEMAS A UN PROCEDIMIENTO Y A UNA VACUNA QUE CONTIENE UN COADYUVANTE TALES COMO 3D-MPL, QS21 Y/O OLIGONUCLEOTIDO CpG, Y/O UNA CITOQUINA O QUIMIOQUINA INMUNOESTIMULADORA. DICHA COMPOSICION QUE CONTIENE LA PROTEINA DE FUSION ES UTIL EN EL TRATAMIENTO DEL CANCER.
PE2012001372A 2007-01-15 2008-01-11 Proteinas de fusion que comprenden un antigeno prame (dage) PE20130324A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0700760A GB0700760D0 (en) 2007-01-15 2007-01-15 Vaccine
GB0701262A GB0701262D0 (en) 2007-01-23 2007-01-23 Vaccine

Publications (1)

Publication Number Publication Date
PE20130324A1 true PE20130324A1 (es) 2013-03-05

Family

ID=39300029

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2012001372A PE20130324A1 (es) 2007-01-15 2008-01-11 Proteinas de fusion que comprenden un antigeno prame (dage)
PE2008000124A PE20081686A1 (es) 2007-01-15 2008-01-11 Proteinas de fusion que comprenden un antigeno prame (dage)

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2008000124A PE20081686A1 (es) 2007-01-15 2008-01-11 Proteinas de fusion que comprenden un antigeno prame (dage)

Country Status (32)

Country Link
US (1) US20080187535A1 (es)
EP (1) EP2114993B1 (es)
JP (1) JP5391080B2 (es)
KR (1) KR20090101313A (es)
CN (1) CN101668770B (es)
AR (1) AR064862A1 (es)
AU (1) AU2008207025B2 (es)
BR (1) BRPI0806463A2 (es)
CA (1) CA2674552A1 (es)
CL (1) CL2008000104A1 (es)
CO (1) CO6210757A2 (es)
CR (1) CR10971A (es)
CY (1) CY1113760T1 (es)
DK (1) DK2114993T3 (es)
DO (1) DOP2009000167A (es)
EA (1) EA016326B1 (es)
ES (1) ES2393812T3 (es)
HK (1) HK1138853A1 (es)
HR (1) HRP20120828T1 (es)
IL (1) IL199663A0 (es)
JO (1) JO2840B1 (es)
MA (1) MA31093B1 (es)
MX (1) MX2009007571A (es)
MY (1) MY153679A (es)
NZ (1) NZ578285A (es)
PE (2) PE20130324A1 (es)
PL (1) PL2114993T3 (es)
PT (1) PT2114993E (es)
SI (1) SI2114993T1 (es)
TW (1) TWI434697B (es)
WO (1) WO2008087102A1 (es)
ZA (1) ZA200904923B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090122426A (ko) * 2007-01-15 2009-11-30 글락소스미스클라인 바이오로지칼즈 에스.에이. 종양 거부 항원 ｎｙ-ｅｓｏ-１ 및 ｌａｇｅ-１을 포함하는 융합 단백질
BRPI1009873A2 (pt) 2009-03-17 2016-03-08 Glaxosmithkline Biolog Sa detecção aperfeiçoada de expressão gênica
CA2763492A1 (en) * 2009-06-05 2010-12-09 The Ohio State University Research Foundation Biomaterials, compositions, and methods
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB201008682D0 (en) * 2010-05-25 2010-07-07 Vib Vzw Epitope tag for affinity based applications
GB201101331D0 (en) * 2011-01-26 2011-03-09 Glaxosmithkline Biolog Sa Compositions and uses
AU2012288926A1 (en) * 2011-07-22 2014-01-16 Glaxosmithkline Biologicals S.A. PRAME purification
GB201114919D0 (en) * 2011-08-30 2011-10-12 Glaxosmithkline Biolog Sa Method
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
RU2590701C2 (ru) * 2013-04-29 2016-07-10 Общество с ограниченной ответственностью "ГеноТехнология" Антигенная композиция и ее терапевтическое применение для профилактики и лечения онкологических заболеваний, рекомбинантная плазмидная днк, обеспечивающая синтез гибридного белка, а также способ получения белка
JP6558699B2 (ja) 2013-10-01 2019-08-14 国立大学法人三重大学 抗原提示を促進するエピトープ間配列を含むｔ細胞誘導ワクチン
CN105254767A (zh) * 2015-11-17 2016-01-20 重庆科润生物医药研发有限公司 一种Protein D与HER2融合蛋白及其制备方法和应用
AU2017367642A1 (en) 2016-11-30 2019-05-30 Advaxis, Inc. Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
CN108264550B (zh) * 2017-01-04 2021-04-23 香雪生命科学技术（广东）有限公司 一种识别源自于prame抗原短肽的tcr
CN108948184B (zh) * 2017-05-22 2021-04-23 香雪生命科学技术（广东）有限公司 一种识别衍生自prame抗原短肽的t细胞受体
CN109400697B (zh) * 2017-08-17 2021-04-23 香雪生命科学技术（广东）有限公司 一种识别prame抗原短肽的tcr及其相关组合物
WO2019061297A1 (zh) * 2017-09-29 2019-04-04 苏州工业园区唯可达生物科技有限公司 一种cd4辅助性t细胞表位融合肽及其疫苗
SG11202004107YA (en) * 2017-11-08 2020-06-29 Advaxis Inc Immunogenic heteroclitic peptides from cancer-associated proteins and methods of use thereof
CN109879957B (zh) * 2017-12-06 2022-03-18 香雪生命科学技术（广东）有限公司 针对prame的高亲和力t细胞受体
WO2021243295A2 (en) * 2020-05-29 2021-12-02 Children's National Medical Center Identification of hla-restricted prame peptide epitopes, prame-specific t cells suitable for "off-the-shelf" treatment of cancer expressing prame
EP4334361A1 (en) 2021-05-05 2024-03-13 Immatics Biotechnologies GmbH Antigen binding proteins specifically binding prame

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
ES2156932T3 (es) * 1993-12-23 2001-08-01 Rmf Dictagene Sa Microparticulas cargadas con antigeno y preparados farmaceuticos que contienen estas microparticulas.
US5830753A (en) * 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
CN1227360C (zh) * 1998-02-05 2005-11-16 史密丝克莱恩比彻姆生物有限公司 Mage家族肿瘤相关抗原衍生物及其编码核酸序列
AU3158900A (en) * 1999-02-25 2000-09-14 Smithkline Beecham Biologicals (Sa) Immunogens comprising a peptide and a carrier derived from h.influenzae protein
CA2376992A1 (en) * 1999-06-29 2001-01-04 Smithkline Beecham Biologicals S.A. Use of cpg as an adjuvant for hiv vaccine
CA2378097A1 (en) * 1999-07-08 2001-01-18 Stressgen Biotechnologies Corporation Induction of a th1-like response in vitro

Also Published As

Publication number Publication date
CY1113760T1 (el) 2016-07-27
ZA200904923B (en) 2012-12-27
CN101668770B (zh) 2013-06-12
SI2114993T1 (sl) 2012-12-31
ES2393812T3 (es) 2012-12-28
BRPI0806463A2 (pt) 2011-09-06
JP2010515444A (ja) 2010-05-13
CO6210757A2 (es) 2010-10-20
TWI434697B (zh) 2014-04-21
EP2114993B1 (en) 2012-08-29
DOP2009000167A (es) 2009-07-15
EP2114993A1 (en) 2009-11-11
AU2008207025B2 (en) 2012-08-23
EA200900795A1 (ru) 2010-02-26
PT2114993E (pt) 2012-11-28
PL2114993T3 (pl) 2013-01-31
CN101668770A (zh) 2010-03-10
HRP20120828T1 (hr) 2012-11-30
JO2840B1 (en) 2014-09-15
HK1138853A1 (en) 2010-09-03
AU2008207025A1 (en) 2008-07-24
EA016326B1 (ru) 2012-04-30
KR20090101313A (ko) 2009-09-24
MA31093B1 (fr) 2010-01-04
AR064862A1 (es) 2009-04-29
TW200902048A (en) 2009-01-16
WO2008087102A1 (en) 2008-07-24
CA2674552A1 (en) 2008-07-24
DK2114993T3 (da) 2012-10-22
PE20081686A1 (es) 2008-12-25
NZ578285A (en) 2011-12-22
CR10971A (es) 2009-09-09
MY153679A (en) 2015-03-13
IL199663A0 (en) 2010-04-15
CL2008000104A1 (es) 2008-07-18
MX2009007571A (es) 2009-07-22
JP5391080B2 (ja) 2014-01-15
US20080187535A1 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
PE20130324A1 (es) Proteinas de fusion que comprenden un antigeno prame (dage)
CY1121632T1 (el) Η rv2386c πρωτεϊνη φυματιωσης, συνθεσεις και χρησεις αυτης
EA202192570A1 (ru) Иммуногенные композиции и вакцины, содержащие пептиды и белки вируса африканской чумы свиней, и их применение
PE20190398A1 (es) Anticuerpos nuevos que se unen especificamente a los epitopos del virus del zika y usos de los mismos
DOP2020000032A (es) Proteínas de unión específicas y sus usos
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
AR112604A1 (es) Receptores de células t, e inmunoterapia usando los mismos
CO2020013588A2 (es) Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos
BR112019011450A2 (pt) células naturais killer modificadas e uso das mesmas
GT201000148A (es) Anticuerpos antimesotelina y usos de los mismos
CL2016001405A1 (es) A peptide mixture
CR20180174A (es) Nuevos péptidos, combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer
UY32812A (es) Anticuerpos humanos de alta afinidad para angiopoyetina -2 humana.
EA201000207A1 (ru) Новые иммуногенные эпитопы для иммунотерапии
CO6480995A2 (es) Construcciones novedosas de proteina del virus de pailoma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv
EA201071297A1 (ru) Новые и действенные пептиды мнс ii класса, полученные из сурвивина
PE20091193A1 (es) Proteinas humanas de union a antigenos del gm-csf
EA201290131A1 (ru) Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний
CY1117214T1 (el) Συνθεση για ελεγχομενη διεγερση των ωοθηκων
ES2337399T3 (es) Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii.
AR067666A1 (es) Proteinas de union al antigeno del receptor de il-18
BR112019012796A2 (pt) proteínas de ligação ao antígeno antineuropilina e métodos de uso das mesmas
CY1119737T1 (el) Νεες συνθεσεις και μεθοδοι
AR114565A1 (es) Proteínas de fusión fc il-22 y métodos de uso
EA202191175A1 (ru) Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры

Legal Events

Date Code Title Description
FC Refusal